Compare · LUCD vs MDLN
LUCD vs MDLN
Side-by-side comparison of Lucid Diagnostics Inc. (LUCD) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LUCD and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $58.79B, about 304.3x LUCD ($193.2M).
- Over the past year, LUCD is down 12.8% and MDLN is up 9.8% - MDLN leads by 22.6 points.
- LUCD has been more active in the news (12 items in the past 4 weeks vs 4 for MDLN).
- MDLN has more recent analyst coverage (25 ratings vs 6 for LUCD).
- Company
- Lucid Diagnostics Inc.
- Medline Inc.
- Price
- $1.09+1.87%
- $44.76+0.65%
- Market cap
- $193.2M
- $58.79B
- 1M return
- -5.22%
- +1.69%
- 1Y return
- -12.80%
- +9.84%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2025
- News (4w)
- 12
- 4
- Recent ratings
- 6
- 25
Lucid Diagnostics Inc.
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. It focuses on patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. The company's lead products include EsoGuard, a laboratory developed esophageal DNA test that examines individuals DNA molecules for the presence or absence of cytosine methylation; and EsoCheck, a cell collection device that collects cells of targeted region of the esophagus. Lucid Diagnostics Inc. was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
Latest LUCD
- PAVmed to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 15, 2026
- SEC Form DEFA14A filed by Lucid Diagnostics Inc.
- SEC Form DEF 14A filed by Lucid Diagnostics Inc.
- Lucid Diagnostics to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 14, 2026
- Amendment: New insider Lee Victoria Tou-Ho claimed ownership of 650,000 shares (SEC Form 3)
- Lucid Diagnostics Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Lucid Diagnostics Announces Closing of $18 Million Underwritten Offering of Common Stock
- SEC Form 424B5 filed by Lucid Diagnostics Inc.
- Lucid Diagnostics Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Lucid Diagnostics Announces $18 Million Underwritten Offering of Common Stock
Latest MDLN
- Amendment: SEC Form SCHEDULE 13G/A filed by Medline Inc.
- SEC Form DEFA14A filed by Medline Inc.
- SEC Form DEF 14A filed by Medline Inc.
- Medline announces first-in-healthcare AI robotics partnership with Symbotic
- Medline to report first quarter 2026 results on May 6, 2026
- Medline launches custom product fulfillment technology called Pick Pack Pro™
- Medline recognizes manufacturing facilities with Golden Cone Safety Award
- Medline receives HIRC Member Choice Awards for supply chain achievement and renews Transparency Badge distinction
- Director Healy Patrick J acquired 577,510 shares, increasing direct ownership by 73% to 1,208,159 units (SEC Form 4)
- Large owner Hellman & Friedman Capital Partners X (Parallel), L.P. sold $1,058,524,148 worth of shares (26,131,237 units at $40.51) and disposed of 2,088,086 shares (SEC Form 4)